Live Ventures CEO Announces Purchase of 55,796 Shares of the Company’s Common Stock in the Open Market
LAS VEGAS, March 28, 2025 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE) (“Live Ventures” or the “Company”), a diversified […]
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology […]
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a […]
NextNRG, Inc. Reports February 2025 Revenue Exceeding January’s Record, Driving Continued Momentum in Smart Fueling Operations
February Revenue up 139% Year-over-Year from $2.1m to $5.9m With Second Consecutive Month of Record Performance, February Revenue Surpasses January […]
Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology […]
Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China
PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) — Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative […]
Meiwu Technology Company Limited Announces 1 for 20 Reverse Share Split
SHENZHEN, China, March 28, 2025 (GLOBE NEWSWIRE) — Meiwu Technology Company Limited (NASDAQ: WNW) (“WNW” or the “Company”), announced today […]
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology […]
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call
LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical […]
NANO Nuclear Energy Bolsters the Engineering Team Overseeing the Development of its ODIN™ Microreactor with Three Additional Leading Professionals
New York, N.Y., March 28, 2025 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), […]
